Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons"

Autoimmunity Reviews

Volumn 11, Issue 8, 2012, Pages 568-571

  Ceccarelli, Fulvia ^a   Chighizola, Cecilia ^b   Finazzi, Guido ^c   Meroni, Pier Luigi ^b   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

Anti phospholipid antibodies; Carriers; Risk factors; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN ANTIBODY; CARDIOLIPIN ANTIBODY; HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; HUMAN; IMMOBILIZATION; LOW DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; RISK FACTORS; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 84861480764     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.10.014     Document Type: Review

References (22)

1. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk?. Curr Rheumatol Rep 2001, 3:271-276.
2. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C., et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560-1567.
3. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011, 20:206-218.
4. Erkan D., Harrison M.J., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56:2382-2391.
5. Erkan D., Yazici Y., Peterson M.G., et al. A cross sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002, 41:924-929.
6. Hereng T., Lambert M., Hachulla E., Samor M., et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008, 17:11-15.
7. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern med 117:303-308.
8. Derksen R.H., de Groot P.G., Kater L., et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis 1993, 52:689-692.
9. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995, 332:993-997.
10. Finazzi G., Brancaccio V., Moia M., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996, 100:530-536.
11. Ruffatti A., Del Ross T., Ciprian M., et al. Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic events in antiphospholipid carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011, 70:1083-1086.
12. Shah N.M., Khamashta, Atsumi T., et al. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998, 7:3-6.
13. Wahl D.G., Bounameaux H., de Moerloose P., et al. Prophylactic antithrombotic therapy for patients with or without antiphospholipid antibodies: do the benefit outweigh the risk? A decision analysis. Arch Intern Med 2000, 160:2042-2048.
14. Erkan D., Merril J.T., Yazici Y., et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001, 44:1466-1469.
15. Tektonidou M.G., Laskari K., Panagiotakos Db, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
16. Kaiser R., Cleveland C.M., Criswell L.A. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68:238-241.
17. Tarr T., Lakos G., Bhattoa H.P., et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007, 32:131-137.
18. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:295-306.
19. Patrono C., Coller B., FitzGerald G.A., et al. Platelet-active drugs: the relationship among dose, effectiveness and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:234S-264S.
20. Barbhaiya M., Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand ?. Curr Rheumat Rep 2011, 13:59-69.
21. Kaul M., Erkan D., Sammaritano L., et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007, 66:927-930.
22. Pengo V., Ruffatti A., Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8:237-242.